Your session is about to expire
← Back to Search
Part 1 - Single Ascending Dose for Obesity
Study Summary
This trial is testing a new drug called DA-1726 in people who are obese but otherwise healthy. The main goal is to see if the drug is safe and well-tolerated when given in
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Who meets the criteria to participate in this medical study?
"Individuals meeting the eligibility criteria must have a body mass index indicative of obesity and fall within the age range of 18 to 65 years old. The trial has openings for up to 81 participants in total."
Are there any vacancies available for patients to participate in this trial?
"The information available on clinicaltrials.gov reveals that this particular research endeavor is not currently seeking volunteers. Its initial posting was made on March 1st, 2024, with the latest revision dated February 7th of the same year. Although inactive now, it's noteworthy that there are an extensive 958 ongoing trials actively enrolling participants."
Does this medical study include individuals aged 85 and above as participants?
"Individuals aged between 18 and 65 are eligible to participate in this trial as per the inclusion criteria. Notably, there are a total of 175 trials focused on individuals under 18 years old, while 608 trials cater to those above the age of 65."
Does the FDA endorse Part 1 - Single Ascending Dose of this study?
"According to our assessment at Power, the safety rating for Part 1 - Single Ascending Dose is a level 1. This reflects that as it is a Phase 1 trial, there exists only minimal data supporting both its safety and effectiveness."
Share this study with friends
Copy Link
Messenger